

Anti-IL-6Ra/CD126 Antibody (Tocilizumab)

Introduction

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting classical and trans Signal. Tocilizumab is being studied in rheumatoid arthritis. Tocilizumab has shown remarkable results in studies of severe COVID-19 viruses.

Product parameters

Alternative Names	Actemra, RoActemra, MRA
Target Accession	P08887
Target	IL-6Ra / CD126
CAS number	375823-41-9
Molecular Weight	145.2 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human IL-6R CHO cells were stained with Anti-IL-6Ra/CD126 Antibody (Tocilizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.4525 nM.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

